Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its
Abingdon Health plc Launch of LVOne Stroke Test by UpFront Diagnostics
UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics
Abingdon Health updates on collaboration with 4TEEN4 Pharmaceuticals
Abingdon Health plc (AIM: ABDX) has provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, focused on the co-development of a companion diagnostic for a potentially life-saving shock therapy.
Abingdon Health plc (AIM: ABDX) $2.5m Contract for clinical self-test development
$2.5m Contract Award for development of clinical self-test
Abingdon Health plc (AIM: ABDX) c.US$2m multiplex diagnostic test contract win
c.US$2m multiplex diagnostic test contract win Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
Abingdon Health plc (AIM: ABDX) Trading update
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
Abingdon Health plc (AIM: ABDX) c. US$2.5m companion diagnostic test contract win
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
Fusion Antibodies (AIM:FAB) Contract win
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with a new stable
Fusion Antibodies (AIM:FAB) OptiMAL R&D Update
OptiMAL® R&D Update
Abingdon Health PLC (AIM:ABDX) Funding award to develop test for malaria parasite
Point-of-care rapid diagnostic test for Plasmodium vivax infection to be developed for in-field testing
Abingdon Health PLC (AIM:ABDX) Appointment of Chief Financial Officer
York, U.K. 19 December 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces the appointment of Tom Hayes as
Abingdon Health plc (AIM:ABDX) Contract win worth up to US$2million across 2025
Contract win: sexually transmitted disease tests Regulatory and clinical trials contract worth up to US$2million across 2025